NOT_YET_RECRUITING

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China

NCT07316062•AstraZeneca

View on ClinicalTrials.gov

Summary

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Detailed Description

The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Stage I-III at initial NSCLC diagnosis
•Aged ≥18 years at first diagnosis of NSCLC
•Timeframe of NSCLC diagnosis:
•For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion Criteria

•NSCLC is not the primary cancer diagnosis
•Patients with a recent history of other tumor or concurrent other tumor
•Patients participating in interventional clinical trials at time of initial diagnosis
•Patients with positive pregnancy status at the time of diagnosis

Locations (1)

Research Site

Beijing, China

Key Dates

Start Date

April 15, 2026

Primary Completion Date

April 30, 2029

Completion Date

April 30, 2029

Last Updated

January 5, 2026

Enrollment

3,000

ESTIMATED participants

Conditions

Non-Small-Cell Lung

Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

RECRUITINGPHASE2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Carcinoma, Non-Small-Cell Lung

View study

RECRUITING

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT04165798

Carcinoma, Non-Small-Cell Lung

View study

RECRUITINGPHASE3